Translational research in pancreatic cancer

Journal of the Pancreas

Volumn 12, Issue 2, 2011, Pages 120-122

  Strimpakos, Alexios S ^a   Syrigos, Konstantinos N ^a   Saif, Muhammad Wasif ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b New York Presbyterian Hospital ^*  (United States)

Author keywords

Erlotinib; Gemcitabine; Molecular targeted therapy; Pancreatic neoplasms; Radiation sensitizing agents

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; APRICOXIB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FOCAL ADHESION KINASE; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROSTAGLANDIN E2; VASCULOTROPIN RECEPTOR 3; VELIPARIB;

ADVANCED CANCER; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CARCINOGENESIS; CAUSE OF DEATH; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAXIMUM TOLERATED DOSE; PANCREAS CANCER; RADIOIMMUNOTHERAPY; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; CYCLOOXYGENASE 2 INHIBITORS; EPITOPES; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MUCINS; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PYRROLES; RADIATION-SENSITIZING AGENTS; SULFONAMIDES; TRANSLATIONAL RESEARCH; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952795942     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615. [PMID 17577041]
2. Strimpakos AS, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008; 27: 495-522. [PMID 18427734]
3. Strimpakos AS, Syrigos KN, Saif MW. The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver 2010; 4: 433-449. [PMID 21253292]
4. Ucar DA, Hochwald SN. FAK and Interacting Proteins as Therapeutic Targets in Pancreatic Cancer. Anticancer Agents Med Chem 2011 Jan 14. [PMID 21235432]
5. Kurenova EV, Liao J, He D, Hunt DL, Chekhau A, Hochwald SN, et al. Effect of a novel FAK inhibitor targeted to the binding site of VEGFR3 on pancreatic cancer proliferation in vitro and in vivo. J Clin Oncol 2011; 29(Suppl. 4):Abstract 214.
6. Kirane AR. Effect of apricoxib, a novel COX-2 inhibitor, on the efficacy of standard therapy in human pancreatic cancer cell lines in vitro and in vivo. J Clin Oncol 2011; 29(Suppl. 4):Abstract 227.
7. Sharkey RM, Karacay H, Govindan SV, Moon S, Mostafa A, Goldenberg DM. Effect of combination radioimmunotherapy (RAIT) and chemoimmunotherapy on therapeutic response and toxicity in xenograft models of human pancreatic carcinoma: First experimental studies. J Clin Oncol 2011; 29(Suppl. 4):Abstract 206.
8. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008; 10:511-545. [PMID 18370854]
9. Tuli R, Surmak A Jr, Herman JM. Effect of diferuloyl methane (curcumin) on radiation-induced inhibition of proliferation and cytotoxicity of pancreatic cancer cells. J Clin Oncol 2011; 29(Suppl. 4):Abstract 222.
10. Tuli R, Surmak A Jr, Blackford A, Leubner A, Jaffee EM, DeWeese TL, Herman JM. Effect of inhibition of poly-(ADP ribose) polymerase on gemcitabine and radiation-induced cytotoxicity of pancreatic cancer cells. J Clin Oncol 2011; 29(Suppl. 4):Abstract 203.
11. Diaz LA, Azad NS, Laheru D, Le DT, Devoe CE, Cosgrove D, et al. NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers. J Clin Oncol 2011; 29(Suppl. 4):Abstract 235.